Onkogeny RAS – prediktivní molekulární marker u kolorektálního karcinomu
Authors:
J. Tomášek 1,2; J. Berkovcová 2,3
Authors place of work:
Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
1; LF MU, Brno
2; 1. úsek diagnostické bioptické patologie, Masarykův onkologický ústav, Brno
3
Published in the journal:
Klin Onkol 2013; 26(5): 366-367
Category:
Oncology Highlights
Zdroje
1. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93(14): 1062–1074.
Štítky
Paediatric clinical oncology Surgery Clinical oncologyČlánok vyšiel v časopise
Clinical Oncology
2013 Číslo 5
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Management of Infections in Palliative and Terminal Cancer Care
- Chylous Ascites as a Serious Complication of the Neuroendocrine Tumor of Ileum – Case Report
- Nephroblastoma – 30-Years Period of its Treatment in the University Hospital Motol, Prague
- Onkogeny RAS – prediktivní molekulární marker u kolorektálního karcinomu